RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Astellas Pharma Stock

Astellas Pharma ROA 2024

Astellas Pharma ROA

0

Ticker

4503.T

ISIN

JP3942400007

WKN

856273

In 2024, Astellas Pharma's return on assets (ROA) was 0, a -91.02% increase from the 0.05 ROA in the previous year.

Astellas Pharma Aktienanalyse

What does Astellas Pharma do?

Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Astellas Pharma's Return on Assets (ROA)

Astellas Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Astellas Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Astellas Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Astellas Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Astellas Pharma stock

What is the Return on Assets (ROA) of Astellas Pharma this year?

The Return on Assets (ROA) of Astellas Pharma is 0 undefined this year.

What was the ROA of Astellas Pharma compared to the previous year?

The ROA of Astellas Pharma has increased by -91.02% compared to the previous year.

What consequences do high ROA have for investors of Astellas Pharma?

A high ROA is advantageous for investors of Astellas Pharma, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Astellas Pharma?

A low ROA can be unfavorable for investors of Astellas Pharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Astellas Pharma affect the company?

An increase in ROA of Astellas Pharma can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Astellas Pharma impact the company?

A reduction in the ROA of Astellas Pharma can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Astellas Pharma?

Some factors that can influence the ROA of Astellas Pharma include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Astellas Pharma important for investors?

The ROA of Astellas Pharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Astellas Pharma take to improve ROA?

To improve ROA, Astellas Pharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Astellas Pharma pay?

Over the past 12 months, Astellas Pharma paid a dividend of 72 JPY . This corresponds to a dividend yield of about 4.67 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 73.66 JPY.

What is the dividend yield of Astellas Pharma?

The current dividend yield of Astellas Pharma is 4.67 %.

When does Astellas Pharma pay dividends?

Astellas Pharma pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Astellas Pharma?

Astellas Pharma paid dividends every year for the past 23 years.

What is the dividend of Astellas Pharma?

For the upcoming 12 months, dividends amounting to 73.66 JPY are expected. This corresponds to a dividend yield of 4.78 %.

In which sector is Astellas Pharma located?

Astellas Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Astellas Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Astellas Pharma from 12/1/2024 amounting to 37 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Astellas Pharma pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Astellas Pharma in the year 2023?

In the year 2023, Astellas Pharma distributed 65 JPY as dividends.

In which currency does Astellas Pharma pay out the dividend?

The dividends of Astellas Pharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Astellas Pharma stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Astellas Pharma

Our stock analysis for Astellas Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.